Tempest Therapeutics Stock Today

TPST Stock  USD 6.30  0.36  5.41%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Tempest Therapeutics is selling for under 6.30 as of the 19th of July 2025; that is 5.41 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 6.25. Tempest Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of November 2012
Category
Healthcare
Classification
Health Care
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.68 M outstanding shares of which 365.69 K shares are at this time shorted by private and institutional investors with about 2.24 trading days to cover. More on Tempest Therapeutics

Moving against Tempest Stock

  0.35INCR INC Research HoldingsPairCorr

Tempest Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CEOLLM JD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01630.0171
Sufficiently Down
Slightly volatile
Total Current Liabilities9.7 M14.2 M
Way Down
Slightly volatile
Non Current Liabilities Total12.3 M8.1 M
Way Up
Slightly volatile
Total Assets64.9 M41.5 M
Way Up
Pretty Stable
Total Current Assets43.3 M31.5 M
Significantly Up
Very volatile
Debt Levels
Tempest Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tempest Therapeutics' financial leverage. It provides some insight into what part of Tempest Therapeutics' total assets is financed by creditors.
Liquidity
Tempest Therapeutics currently holds 15.37 M in liabilities with Debt to Equity (D/E) ratio of 0.49, which is about average as compared to similar companies. Tempest Therapeutics has a current ratio of 2.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tempest Therapeutics' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

860,062
Tempest Therapeutics (TPST) is traded on NASDAQ Exchange in USA. It is located in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 and employs 24 people. Tempest Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.52 M. Tempest Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.68 M outstanding shares of which 365.69 K shares are at this time shorted by private and institutional investors with about 2.24 trading days to cover. Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check Tempest Therapeutics Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Tempest Therapeutics is $24.52 Million. About 88.15 % of Tempest Therapeutics outstanding shares are held by general public with 0.12 (%) owned by insiders and only 11.73 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Tempest Ownership Details

Tempest Stock Institutional Holders

InstituionRecorded OnShares
Advisor Group Holdings, Inc.2024-12-31
25.4 K
Simplex Trading, Llc2024-12-31
18.9 K
Maytech Global Investments, Llc2024-12-31
10 K
Federation Des Caisses Desjardins Du Quebec2024-12-31
3.8 K
Millstone Evans Group, Llc2024-12-31
800
Sbi Securities Co Ltd2025-03-31
767
Bank Of America Corp2024-12-31
331
Parallel Advisors, Llc2025-03-31
236
Atlantic Trust Group, Llc2024-12-31
133
Versant Venture Management Llc2025-03-31
3.5 M
Blackrock Inc2024-12-31
551.9 K
View Tempest Therapeutics Diagnostics

Tempest Therapeutics Historical Income Statement

At this time, Tempest Therapeutics' Other Operating Expenses is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 15.6 M in 2025, whereas EBITDA is likely to drop (42.1 M) in 2025. View More Fundamentals

Tempest Stock Against Markets

Tempest Therapeutics Corporate Management

Nicholas MaestasVP SecretaryProfile
Justin CPATreasurer ControllerProfile
Dr DubenskyPres DirectorProfile
Justin TrojanowskiTreasurer ControllerProfile
RAC SakaiHead QualityProfile
Samuel MDExecutive OfficerProfile
Petpiboon PrasitActing DirectorProfile

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.